6 Aug 2012 14:25
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Issue of equity and Directors' shareholdings
6 August 2012, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that all three Non-Executive Directors of the Company have taken part of their fees for the half-year ended 31 July 2012 in ordinary shares.
The new ordinary shares were issued on 3 August 2012 at a price of 36.0 pence per share, this being the average of the closing mid-market prices for the five business days ending on the last date of the period (31 July 2012). The allotment and total holdings following this allotment are shown below.
Director | Shares allotted 3 August 2012 | Ordinary shares held following allotment (% of current issued share capital) | Options over ordinary shares held (% of current issued share capital) |
Oliver James | 7,500 | 110,500 (0.08%) | 143,020 (0.10%) |
Rajesh Chopra | 8,122 | 8,122 (0.006%) | 0 |
Brad Hoy | 8,500 | 8,500 (0.006%) | 105,000 (0.08%) |
Application has been made to admit the 24,122 new ordinary shares to trading on AIM and dealings in the new ordinary shares are expected to commence on 10 August 2012. Following admission the number of ordinary shares in issue in the Company will be 138,198,359. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Services Authority's Disclosure and Transparency Rules.
Contacts:
e-Therapeutics plc
Daniel Elger
Tel: +44 (0) 7909 915 068
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Andrew Burnett / Fred Walsh
Tel: +44 (0) 20 7459 3600
www.panmure.com